Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples
Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMyco...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1998 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: European journal of clinical microbiology & infectious diseases - 1982, 17(1998) vom: März, Seite 189-192 |
| Übergeordnetes Werk: |
volume:17 ; year:1998 ; month:03 ; pages:189-192 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ206290918 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ206290918 | ||
| 003 | DE-627 | ||
| 005 | 20230505195618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1998 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ206290918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| 264 | 1 | |c 1998 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Gamboa, F. |4 oth | |
| 700 | 1 | |a Cardona, P. J. |4 oth | |
| 700 | 1 | |a Manterola, J. M. |4 oth | |
| 700 | 1 | |a Lonca, J. |4 oth | |
| 700 | 1 | |a Matas, L. |4 oth | |
| 700 | 1 | |a Padilla, E. |4 oth | |
| 700 | 1 | |a Manzano, J. R. |4 oth | |
| 700 | 1 | |a Ausina, V. |4 oth | |
| 773 | 0 | 8 | |i in |t European journal of clinical microbiology & infectious diseases |d 1982 |g 17(1998) vom: März, Seite 189-192 |w (DE-627)NLEJ188994467 |w (DE-600)1459049-9 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:1998 |g month:03 |g pages:189-192 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01691116 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 1998 |c 3 |h 189-192 |g 4 | ||
| matchkey_str |
article:14354373:1998----::vlainfcmecapoesafreetoorfmirssacimcbceimueclssietyrmep |
|---|---|
| hierarchy_sort_str |
1998 |
| publishDate |
1998 |
| allfields |
(DE-627)NLEJ206290918 DE-627 ger DE-627 rakwb eng Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. Springer Online Journal Archives 1860-2002 Gamboa, F. oth Cardona, P. J. oth Manterola, J. M. oth Lonca, J. oth Matas, L. oth Padilla, E. oth Manzano, J. R. oth Ausina, V. oth in European journal of clinical microbiology & infectious diseases 1982 17(1998) vom: März, Seite 189-192 (DE-627)NLEJ188994467 (DE-600)1459049-9 1435-4373 nnns volume:17 year:1998 month:03 pages:189-192 extent:4 http://dx.doi.org/10.1007/BF01691116 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 17 1998 3 189-192 4 |
| spelling |
(DE-627)NLEJ206290918 DE-627 ger DE-627 rakwb eng Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. Springer Online Journal Archives 1860-2002 Gamboa, F. oth Cardona, P. J. oth Manterola, J. M. oth Lonca, J. oth Matas, L. oth Padilla, E. oth Manzano, J. R. oth Ausina, V. oth in European journal of clinical microbiology & infectious diseases 1982 17(1998) vom: März, Seite 189-192 (DE-627)NLEJ188994467 (DE-600)1459049-9 1435-4373 nnns volume:17 year:1998 month:03 pages:189-192 extent:4 http://dx.doi.org/10.1007/BF01691116 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 17 1998 3 189-192 4 |
| allfields_unstemmed |
(DE-627)NLEJ206290918 DE-627 ger DE-627 rakwb eng Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. Springer Online Journal Archives 1860-2002 Gamboa, F. oth Cardona, P. J. oth Manterola, J. M. oth Lonca, J. oth Matas, L. oth Padilla, E. oth Manzano, J. R. oth Ausina, V. oth in European journal of clinical microbiology & infectious diseases 1982 17(1998) vom: März, Seite 189-192 (DE-627)NLEJ188994467 (DE-600)1459049-9 1435-4373 nnns volume:17 year:1998 month:03 pages:189-192 extent:4 http://dx.doi.org/10.1007/BF01691116 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 17 1998 3 189-192 4 |
| allfieldsGer |
(DE-627)NLEJ206290918 DE-627 ger DE-627 rakwb eng Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. Springer Online Journal Archives 1860-2002 Gamboa, F. oth Cardona, P. J. oth Manterola, J. M. oth Lonca, J. oth Matas, L. oth Padilla, E. oth Manzano, J. R. oth Ausina, V. oth in European journal of clinical microbiology & infectious diseases 1982 17(1998) vom: März, Seite 189-192 (DE-627)NLEJ188994467 (DE-600)1459049-9 1435-4373 nnns volume:17 year:1998 month:03 pages:189-192 extent:4 http://dx.doi.org/10.1007/BF01691116 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 17 1998 3 189-192 4 |
| allfieldsSound |
(DE-627)NLEJ206290918 DE-627 ger DE-627 rakwb eng Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. Springer Online Journal Archives 1860-2002 Gamboa, F. oth Cardona, P. J. oth Manterola, J. M. oth Lonca, J. oth Matas, L. oth Padilla, E. oth Manzano, J. R. oth Ausina, V. oth in European journal of clinical microbiology & infectious diseases 1982 17(1998) vom: März, Seite 189-192 (DE-627)NLEJ188994467 (DE-600)1459049-9 1435-4373 nnns volume:17 year:1998 month:03 pages:189-192 extent:4 http://dx.doi.org/10.1007/BF01691116 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 17 1998 3 189-192 4 |
| language |
English |
| source |
in European journal of clinical microbiology & infectious diseases 17(1998) vom: März, Seite 189-192 volume:17 year:1998 month:03 pages:189-192 extent:4 |
| sourceStr |
in European journal of clinical microbiology & infectious diseases 17(1998) vom: März, Seite 189-192 volume:17 year:1998 month:03 pages:189-192 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
European journal of clinical microbiology & infectious diseases |
| authorswithroles_txt_mv |
Gamboa, F. @@oth@@ Cardona, P. J. @@oth@@ Manterola, J. M. @@oth@@ Lonca, J. @@oth@@ Matas, L. @@oth@@ Padilla, E. @@oth@@ Manzano, J. R. @@oth@@ Ausina, V. @@oth@@ |
| publishDateDaySort_date |
1998-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188994467 |
| id |
NLEJ206290918 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ206290918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505195618.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ206290918</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gamboa, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cardona, P. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manterola, J. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lonca, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matas, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padilla, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manzano, J. R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ausina, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">European journal of clinical microbiology & infectious diseases</subfield><subfield code="d">1982</subfield><subfield code="g">17(1998) vom: März, Seite 189-192</subfield><subfield code="w">(DE-627)NLEJ188994467</subfield><subfield code="w">(DE-600)1459049-9</subfield><subfield code="x">1435-4373</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:189-192</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01691116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">1998</subfield><subfield code="c">3</subfield><subfield code="h">189-192</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188994467 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1435-4373 |
| topic_title |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f g fg p j c pj pjc j m m jm jmm j l jl l m lm e p ep j r m jr jrm v a va |
| hierarchy_parent_title |
European journal of clinical microbiology & infectious diseases |
| hierarchy_parent_id |
NLEJ188994467 |
| hierarchy_top_title |
European journal of clinical microbiology & infectious diseases |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188994467 (DE-600)1459049-9 |
| title |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| spellingShingle |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| ctrlnum |
(DE-627)NLEJ206290918 |
| title_full |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| journal |
European journal of clinical microbiology & infectious diseases |
| journalStr |
European journal of clinical microbiology & infectious diseases |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1998 |
| contenttype_str_mv |
zzz |
| container_start_page |
189 |
| container_volume |
17 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
evaluation of a commercial probe assay for detection of rifampin resistance inmycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| title_auth |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| abstract |
Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. |
| abstractGer |
Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. |
| abstract_unstemmed |
Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples |
| url |
http://dx.doi.org/10.1007/BF01691116 |
| remote_bool |
true |
| author2 |
Gamboa, F. Cardona, P. J. Manterola, J. M. Lonca, J. Matas, L. Padilla, E. Manzano, J. R. Ausina, V. |
| author2Str |
Gamboa, F. Cardona, P. J. Manterola, J. M. Lonca, J. Matas, L. Padilla, E. Manzano, J. R. Ausina, V. |
| ppnlink |
NLEJ188994467 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T06:43:40.177Z |
| _version_ |
1803810997722415104 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ206290918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505195618.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ206290918</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of a commercial probe assay for detection of rifampin resistance inMycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A commercial assay (Inno-Line Probe Assay; Innogenetics, Belgium) was evaluated to determine its ability to detect rifampin resistance inMycobacterium tuberculosis directly from clinical specimens. Fifty-nine selected specimens (42 respiratory and 17 nonrespiratory) culture positive forMycobacterium tuberculosis were tested along with their corresponding isolates in culture. The results were compared with those obtained by in vitro susceptibility testing. The results of the line probe assay to detect rifampin resistance inMycobacterium tuberculosis present in clinical specimens and in cultured isolates were concordant for 58 of 59 (98.3%) isolates (95% confidence limits = 90.9–99.9%). The line probe assay failed only once, when a fecal specimen was tested; no amplification was observed due to the presence of inhibitory compounds. The most frequently observed mutation was His526→Asp (58.7%), followed by the His526→Tyr (23.9%); together, they represented 82.6% of rifampin-resistant samples. In conclusion, the Inno-Line Probe Assay is a rapid, useful method for detecting the presence ofMycobacterium tuberculosis complex and its resistance to rifampin directly from clinical specimens and culture. Moreover, since rifampin resistance is a potential marker for multidrug resistance inMycobacterium tuberculosis, this assay may constitute an important tool for the control of tuberculosis.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gamboa, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cardona, P. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manterola, J. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lonca, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matas, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padilla, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manzano, J. R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ausina, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">European journal of clinical microbiology & infectious diseases</subfield><subfield code="d">1982</subfield><subfield code="g">17(1998) vom: März, Seite 189-192</subfield><subfield code="w">(DE-627)NLEJ188994467</subfield><subfield code="w">(DE-600)1459049-9</subfield><subfield code="x">1435-4373</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:189-192</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01691116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">1998</subfield><subfield code="c">3</subfield><subfield code="h">189-192</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.40096 |